To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
116th Congress (2019–2021)
This bill was introduced on April 3, 2019, in a previous session of Congress, but it did not receive a vote.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
16 Cosponsors (12 Democrats, 4 Republicans)
Position statements
What legislators are saying
“Bipartisan Schrader, Carter Bill to Keep Drug Costs Down Passes Through Health Subcommittee”
—
Rep. Kurt Schrader [D-OR5, 2009-2022]
(Sponsor)
on Mar 27, 2019
“Dingell, Health Subcommittee Advance Bills to Lower Prescription Drug Costs & Make Healthcare More Affordable”
—
Rep. Debbie Dingell [D-MI6]
(Co-sponsor)
on Mar 27, 2019
“Olson Slams Democrats For Playing Politics With Affordable Prescription Drugs”
—
Rep. Pete Olson [R-TX22, 2009-2020]
on May 16, 2019
More statements at ProPublica Represent...
What stakeholders are saying
History
|
Jan 31, 2019
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
Mar 13, 2019
|
|
Considered by Health
A committee held a hearing or business meeting about the bill.
|
|
Mar 27, 2019
|
|
Considered by Health
A committee held a hearing or business meeting about the bill.
|
|
Apr 3, 2019
|
|
Ordered Reported
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee. |
|
May 2, 2019
|
|
Reported by House Committee on Energy and Commerce
A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions. |
H.R. 938 (116th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 938. This is the one from the 116th Congress.
This bill was introduced in the 116th Congress, which met from Jan 3, 2019 to Jan 3, 2021. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 938 — 116th Congress: BLOCKING Act of 2019.” www.GovTrack.us. 2019. March 30, 2023 <https://www.govtrack.us/congress/bills/116/hr938>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
